AMP Biotech Research (ampbioresearch.com) is pleased to announce its list of bipharma company picks for Q1 2017.
As discussed in our investment philosophy, we like undervalued companies with multiple drug candidates recently approved and/or in significant clinical trials, or with at least enough cash to provide runway through multiple value-driving events. Consequently, several of our Q4 2016 companies remain on our pick-to-click list for Q1 2017. These companies include Alkermes (ALKS), Nektar Therapeutics (NKTR), FibroGen (FGEN), UniQure (QURE), and CytRx (CYTR). New companies added that were not on our Q4 2016 list include Synergy Pharmaceuticals (SGYP), Merrimack Pharmaceuticals (MACK), and Synthetic Biologics (SYN).
Noteworthy Upcoming Catalysts for our Q1 Picks:
Alkermes has an important pre-NDA meeting with the FDA regarding next steps for ALKS-5461
Nektar Therapeutics will report Ph3 data for NKTR-181 in chronic lower back pain
FibroGen will report two events including updated Ph2 data for pamrevlumab in pancreatic cancer and Ph3 data for roxadustat in CKD
UniQure will report Ph1/2 results from AMT-110 in Sanfilippo B patients
CytRx will report Ph2 data for Aldoxorubicin in relapsed/refractory SCLC
Synergy Pharmaceuticals has a scheduled PDUFA date on Jan. 29th for plecanatide in chronic idiopathic constipation
Merrimack Pharmaceuticals will announce the results of its clinical trial refocusing and possibly a corporate transaction
Synthetic Biologics will report Ph2b data for SYN-004 in protecting patients on IV beta lactams from C. diff infection
Each company AMP selects has a unique investment thesis that is explained in the full report. It is important to remember that investment theses change over time. When anything fundamental to a company changes, we will provide an update to our report, which is free of charge in this introductory period. As always, we encourage our readers to fully evaluate each company prior to making any investment decision. The best diligence uses as many resources as possible and we hope to be among those you choose.